TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04544462

Intervention type: OTHER
Intervention: M2 Test
Description: DNA will be extracted from saliva samples obtained from participants. Genetic testing will be performed to screen for the M2 mutation and determine the carrier status of each patient and partner.
Study: NCT02751086

Intervention type: PROCEDURE
Intervention: Laparoscopic Gastrectomy
Description: Minimally invasive surgical approach performed through traditional laparoscopy.
Study: NCT04271150

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Self-etch
Description: Universal adhesive with self-etch mode

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total-etch
Description: Universal adhesive with total-etch mode
Study: NCT00853931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Panitumumab 6 mg/kg will be administered by intravenous infusion every 2 weeks (Q2W), +/- 3 days, (eg, week 1, 3, 5 \[i.e. Cycles 1, 2, 3, etc.\]) until disease progression or intolerance panitumumab as determined by the investigator.
Study: NCT01347879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Visonac PDT
Description: cream application prior to illumination with red light

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle cream with PDT
Description: placebo/vehicle cream application prior to illumination with red light
Study: NCT01135108

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KAI-1678
Description: KAI-1678 IV Infusion
Study: NCT01047904

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acclarent Iontophoresis System
Description: Administration of local anesthesia using the Acclarent Iontophoresis System
Study: NCT03631459

Intervention type: DRUG
Intervention: Kanglaite Injection/Capsules
Description: Kanglaite injection 200 mL, iv. gtt qd×7d or more, followed by Kanglaite capsule 0.45g×6 tablets qid po×14d as one cycle for at least 4 cycles
Study: NCT04208191

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quality Improvement Collaborative
Description: Facilities that participated in a QI collaborative to improve PCC for MH and FP services

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quality Improvement Collaborative
Description: Facilities that participated in a QI collaborative to improve PCC for MH and FP services
Study: NCT03351127

Intervention type: RADIATION
Intervention: Carotid ultrasound examination
Description: Carotid pulse wave velocity of all participants were measured by ultrafast ultrasound imaging technology using SuperSonic Imagine's Aixplorer ultrasound system.

Intervention type: RADIATION
Intervention: Carotid ultrasound examination
Description: Carotid pulse wave velocity of all participants were measured by ultrafast ultrasound imaging technology using SuperSonic Imagine's Aixplorer ultrasound system.

Intervention type: RADIATION
Intervention: Carotid ultrasound examination
Description: Carotid pulse wave velocity of all participants were measured by ultrafast ultrasound imaging technology using SuperSonic Imagine's Aixplorer ultrasound system.

Intervention type: RADIATION
Intervention: Carotid ultrasound examination
Description: Carotid pulse wave velocity of all participants were measured by ultrafast ultrasound imaging technology using SuperSonic Imagine's Aixplorer ultrasound system.

Intervention type: RADIATION
Intervention: Carotid ultrasound examination
Description: Carotid pulse wave velocity of all participants were measured by ultrafast ultrasound imaging technology using SuperSonic Imagine's Aixplorer ultrasound system.

Intervention type: RADIATION
Intervention: Carotid ultrasound examination
Description: Carotid pulse wave velocity of all participants were measured by ultrafast ultrasound imaging technology using SuperSonic Imagine's Aixplorer ultrasound system.
Study: NCT01389024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Description: Hydroxyurea solution 100 mg/ml with a starting dose of 20 mg/kg/day by mouth once daily and escalation by 5 mg/kg/day every 8 weeks until hematological toxicity, an Absolute Neutrophil Count of 2000 to 4000/ul, or a maximum dose of 35 mg/kg/day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sucrose solution 0.2 ml/kg/day by mouth once a day with blinded dose escalation of 0.05 ml/kg/day to match the frequency of dose escalation in the hydroxyurea arm.
Study: NCT03586037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-2011 10/20 mg
Description: AD-2011 10/20 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-2011 10/20 mg
Description: AD-2011 10/20 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-2011 10/20 mg
Description: AD-2011 10/20 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-2011 10/20 mg
Description: AD-2011 10/20 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-2011 10/20 mg
Description: AD-2011 10/20 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-2011 10/20 mg
Description: AD-2011 10/20 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-2012 80mg
Description: AD-2012 80mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-2012 80mg
Description: AD-2012 80mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-2012 80mg
Description: AD-2012 80mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-2012 80mg
Description: AD-2012 80mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-2012 80mg
Description: AD-2012 80mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-2012 80mg
Description: AD-2012 80mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-2011 10/20 mg + AD-2012 80mg
Description: AD-2011 10/20 mg + AD-2012 80mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-2011 10/20 mg + AD-2012 80mg
Description: AD-2011 10/20 mg + AD-2012 80mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-2011 10/20 mg + AD-2012 80mg
Description: AD-2011 10/20 mg + AD-2012 80mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-2011 10/20 mg + AD-2012 80mg
Description: AD-2011 10/20 mg + AD-2012 80mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-2011 10/20 mg + AD-2012 80mg
Description: AD-2011 10/20 mg + AD-2012 80mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-2011 10/20 mg + AD-2012 80mg
Description: AD-2011 10/20 mg + AD-2012 80mg tablet
Study: NCT02361853

Intervention type: OTHER
Intervention: Exposure: abundance of Immature Myeloid Cells counts in blood samples

Intervention type: OTHER
Intervention: Exposure: abundance of Immature Myeloid Cells counts in blood samples

Intervention type: OTHER
Intervention: Exposure: abundance of Immature Myeloid Cells counts in blood samples

Intervention type: OTHER
Intervention: Exposure: abundance of Immature Dentritic Cells counts in blood samples

Intervention type: OTHER
Intervention: Exposure: abundance of Immature Dentritic Cells counts in blood samples

Intervention type: OTHER
Intervention: Exposure: abundance of Immature Dentritic Cells counts in blood samples

Intervention type: OTHER
Intervention: Exposure: abundance of Immature monocytes counts in blood samples

Intervention type: OTHER
Intervention: Exposure: abundance of Immature monocytes counts in blood samples

Intervention type: OTHER
Intervention: Exposure: abundance of Immature monocytes counts in blood samples

Intervention type: OTHER
Intervention: Exposure: abundance of Immature neutrophils counts in blood samples

Intervention type: OTHER
Intervention: Exposure: abundance of Immature neutrophils counts in blood samples

Intervention type: OTHER
Intervention: Exposure: abundance of Immature neutrophils counts in blood samples
Study: NCT01273727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: intravitreal implant 0.7 mg 6 month duration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: intravitreal implant 0.7 mg duration 6 months
Study: NCT01661660

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: observationnal
Description: Observation during a physical exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: observationnal
Description: Observation during a physical exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: observationnal
Description: Observation during a physical exercise
Study: NCT00768716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: 2 x 500 mg by mouth once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: 2 x 500 mg by mouth once
Study: NCT02553616

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention to Promote Healthy Behaviors
Description: Six individualized sessions (30 minutes each) are delivered to each participant randomized to receive the intervention.
Study: NCT01282983

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fiber
Description: The study consists of 21 days consumption of Orange juice. The volunteers will be instructed to consume 200ml of juice twice a day (1 pack of 200ml at lunch and one at dinner) with 4grams of fiber in each pack.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The study consists of 21 days consumption of Orange juice. The volunteers will be instructed to consume 200ml of juice twice a day (1 pack of 200ml at lunch and one at dinner) without fiber.
Study: NCT02880306

Intervention type: OTHER
Intervention: RA
Description: RA was diagnosed based on the 1987 American College of Rheumatology diagnostic criteria
Study: NCT05361083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F18CETO
Description: Injection of F18CETO or O15water followed by PET/CT
Study: NCT04120064

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: Large, one time dose of 300,000 IU oral cholecalciferol or daily 5,000 IU oral cholecalciferol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: Large, one time dose of 300,000 IU oral cholecalciferol or daily 5,000 IU oral cholecalciferol
Study: NCT02316821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RTA 402

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT05569733

Intervention type: DIAGNOSTIC_TEST
Intervention: simultaneous fluor-18 fluorodeoxyglucose (FDG) positron emission tomography with magnetic resonance imaging (PET/MRI)
Description: All subjects fast at least for 4 hours prior to 18F-FDG injection. 18F-FDG is injected intravenously (150 megabecquerel (MBq)) in standard ambient conditions, supine in a dark, noise free room with eyes and ears open. 18F-FDG PET images are acquired for 20 min on a simultaneous GE Signa 3 Tesla (3T) PET/MR scanner with integrated Time-of-Flight (TOF) (GE Healthcare, Chicago, USA). Simultaneous with the 18F-FDG PET/MR acquisition, zero-echo-time (ZTE) MR data are acquired for attenuation correction and a 3D volumetric T1-weighted BRAVO MR sequence using a vendor supplied high-resolution 8-channel phased array head coil (GE Healthcare, Milwaukee, USA).

Intervention type: DIAGNOSTIC_TEST
Intervention: simultaneous fluor-18 fluorodeoxyglucose (FDG) positron emission tomography with magnetic resonance imaging (PET/MRI)
Description: All subjects fast at least for 4 hours prior to 18F-FDG injection. 18F-FDG is injected intravenously (150 megabecquerel (MBq)) in standard ambient conditions, supine in a dark, noise free room with eyes and ears open. 18F-FDG PET images are acquired for 20 min on a simultaneous GE Signa 3 Tesla (3T) PET/MR scanner with integrated Time-of-Flight (TOF) (GE Healthcare, Chicago, USA). Simultaneous with the 18F-FDG PET/MR acquisition, zero-echo-time (ZTE) MR data are acquired for attenuation correction and a 3D volumetric T1-weighted BRAVO MR sequence using a vendor supplied high-resolution 8-channel phased array head coil (GE Healthcare, Milwaukee, USA).
Study: NCT01950806

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pecan-containing diet

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Nut-free diet
Study: NCT02267733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzone
Description: Fluzone High-Dose will be administered with a planned booster at 30 days post initial administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzone
Description: Fluzone High-Dose will be administered with a planned booster at 30 days post initial administration
Study: NCT03216954

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol
Description: During each arm, subjects will receive doses of alcohol, designed to raise BALs to 0.015 and 0.03 g/dl.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol
Description: During each arm, subjects will receive doses of alcohol, designed to raise BALs to 0.015 and 0.03 g/dl.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Alcohol
Description: During each arm, subjects will receive doses of alcohol, designed to raise BALs to 0.015 and 0.03 g/dl.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Subjects will receive placebo capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine
Description: Subjects will receive n-acetyl cysteine capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine
Description: Subjects will receive n-acetyl cysteine capsules
Study: NCT02941237

Intervention type: DEVICE
Group type: OTHER
Intervention: Pulse oximeter
Description: Time taken to measure oxygen saturation.~Completion of usability questionnaire

Intervention type: DEVICE
Group type: OTHER
Intervention: Pulse oximeter
Description: Time taken to measure oxygen saturation.~Completion of usability questionnaire
Study: NCT03712228

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Factor XIIa antagonist monoclonal antibody
Description: Factor XIIa antagonist monoclonal antibody for intravenous and subcutaneous use

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Factor XIIa antagonist monoclonal antibody
Description: Factor XIIa antagonist monoclonal antibody for intravenous and subcutaneous use

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Factor XIIa antagonist monoclonal antibody
Description: Factor XIIa antagonist monoclonal antibody for intravenous and subcutaneous use

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Factor XIIa antagonist monoclonal antibody
Description: Factor XIIa antagonist monoclonal antibody for intravenous and subcutaneous use

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Buffer without active ingredient
Study: NCT01287780

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Collagen-gentamicin sponge
Description: A 10 by 10 cm sponge consisting of 280 mg collagen and 130 mg gentamicin.Two sponges are inserted during hemiarthroplasty surgery, one in the joint and one underneath the fascia at the time of surgical closure.
Study: NCT02405286

Intervention type: OTHER
Intervention: Upper gastrointestinal endoscopy
Description: Upper gastrointestinal endoscopy, if stigmata of recent hemorrhage are seen, varices are either injected with ethanolamine or banded, depending on the clinical setting and availability .
Study: NCT03567226

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WeChat Group
Description: Consenting participants will be randomized to either the intervention or the control arm after successfully wearing an accelerometer for one week. The WeChat Group will be a community forum to share information, encourage each other, and receive communications from the study team. In addition, the study team will disseminate the following information through the group:~1. Daily/Weekly Reminders to exercise~2. Health education materials regarding glaucoma and general health and exercise~3. Motivational content~4. Surveys to gauge what information participants found most interesting and useful to help them exercise

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Counselling
Description: Study participants in the control group will receive a handout telling them to increase walking and will be counseled that walking may be helpful for the eye at the return visit
Study: NCT02106026

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preventive education
Description: The intervention group received education to facilitate successful breastfeeding and symptom management as nipple pain. This was supported by strategies designed to (1) prevent problems associated with breastfeeding (nipple lesions, cracks and mastitis), (2) perform breast-care procedures, (3) strengthen information about the advantages of maternal breastfeeding (nutritional support, importance as food for the baby, availability, post-partum recovery) and (4) provide asepsis and hygiene measures.
Study: NCT03153917

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: melatonin and cortisol sampling
Description: The study will take place over 15 days during which the nurses will wear an actigraphic wristband and will fulfill a sleep log. During 3 periods of 24 hours selected during these 15 days, including a 12h day shift (Day 2), a 12h night shift (Day 8) and a rest (Day 13), the participants will collect their urine by 4 to 8 hour periods, note the corresponding urine volumes and for each period, sample a 5 mL tube which will be analyzed later (6-sulfatoxymelatonin and urinary cortisol assays). The subjects will complete questionnaires at the beginning of the study (Horne and Ostberg, Insomnia Severity Index, Epworth, Pichot, Hospital Anxiety and Depression) and the days corresponding to the urine sampling (Karolinska and St Mary Hospital).
Study: NCT03365921

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Participants would receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) intramuscularly at 0, 1, 6 month.
Description: Participants would receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) intramuscularly at 0, 1, 6 month.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Participants would receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) intramuscularly at 0, 1, 6 month.
Description: Participants would receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) intramuscularly at 0, 1, 6 month.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Participants would receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) intramuscularly at 0, 1, 6 month.
Description: Participants would receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) intramuscularly at 0, 1, 6 month.
Study: NCT04279808

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dilator depth
Description: For soft tissue dilation just after guidewire insertion in central venous catheterization through the right internal jugular vein, investigators will measure the distance between the skin puncture site and outside of anterior wall of the vein with real-time ultrasonography in the measured depth group. Next, practitioner will insert the dilator by the measured length and continue to insert the central venous catheter. For the conventional group as a control group, practitioner will perform the central venous catheterization with a manner used routinely by the practitioner.
Study: NCT02462382

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthroscopic Rotator Cuff Repair
Description: During arthroscopic rotator cuff surgery, the surgeon inserts a small camera, called an arthroscope, into your shoulder joint. The camera displays pictures on a television screen, and your surgeon uses these images to guide miniature surgical instruments to repair the torn ligament.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Arthroscopic Rotator Cuff Repair
Description: During arthroscopic rotator cuff surgery, the surgeon inserts a small camera, called an arthroscope, into your shoulder joint. The camera displays pictures on a television screen, and your surgeon uses these images to guide miniature surgical instruments to repair the torn ligament.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: The study group will receive a pump with study drug attached to a catheter placed into the shoulder area by the anesthesiologist.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: The control group will receive a pump with saine attached to a catheter placed into the shoulder area by the anesthesiologist.
Study: NCT02010970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group 1 AZD3293
Description: AZD3293 oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group 2 AZD3293
Description: AZD3293 oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group 3 AZD3293
Description: AZD3293 oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group 1 Itraconazole
Description: itraconazole capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group 2 Diltiazem
Description: Diltiazem ER tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group 3 Midazolam
Description: midazolam syrup
Study: NCT02536131

Intervention type: OTHER
Group type: OTHER
Intervention: Gut-directed hypnotherapy
Description: relaxation technique with hypnotic induction and suggestions aimed at fostering sense of control, acceptance and calming of bowels.
Study: NCT03235765

Intervention type: DIAGNOSTIC_TEST
Intervention: MACROGEN Pan Cancer Panel (Tier 2)
Description: This study will utilize a MACROGEN Pan Cancer Panel (Tier 2), which is a hybrid capture-based NGS assay interrogating the coding regions of 170 cancer-related genes.
Study: NCT01435577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapentadol
Description: 30 mg per administration, maximum 12 administrations over 48 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Maximum 12 administrations over 48 hours
Study: NCT01968213

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rucaparib
Description: Oral tablets administered twice daily with 8 oz (240 mL) of water on an empty stomach or with food; 28-day cycles of treatment. Doses should be taken as close to 12 hours apart as possible, preferably at the same times every day. Tablets should be swallowed whole.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablets administered twice daily with 8 oz (240 mL) of water on an empty stomach or with food; 28-day cycles of treatment. Doses should be taken as close to 12 hours apart as possible, preferably at the same times every day. Tablets should be swallowed whole.
Study: NCT02957682

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Praluent (Alirocumab)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo